人重组干扰素-α-2b治疗子宫内膜异位症的临床分析

摘要

Objective Observation and analysis of recombinant human interferon -α -2 b in treatment of endometriosis clinical efficacy. Methods From March 2010 to March 2012 in our hospital patients without endometriosis in 56 cases, in accordance with the randomly divided into observation group and control group, each with 28 cases, the observation group used recombinant human interferon -α -2 b treatment, control group using the Gore Sherry Lin treatment, observation and comparison of two treatment. Results The two groups of postoperative serum CA 125, EMAb levels after 1, 2, and 3 months and preoperative contrast obvious difference (P<0.05), with statistical signifcance; two groups during treatment of adverse drug reaction rates were compared with the presence of certain difference (P<0.05), with statistical signifcance. Conclusion Recombinant human interferon -α-2 b in the treatment of endometriosis clinical curative effect, and the routine use of Gore Sherry Lin therapy effect is similar, adverse drug reactions performed in the early use of more, but of short duration, after stopping drug can disappear, high safety.%　　目的观察分析人重组干扰素-α-2 b治疗子宫内膜异位症的临床疗效。方法选取2010年6月-2012年6月子宫内膜异位症的患者56例，按照随机数字法分成观察组和对照组，各28例，观察组使用人重组干扰素-α-2 b治疗，对照组使用戈舍瑞林治疗，观察对比两组治疗效果。结果两组术后血清CA 125、EMAb水平术后1、2、3个月与术前对比存在明显差异（P＜0.05），具有统计学意义；两组治疗期间药物不良反应发生率进行比较存在一定差异（P＜0.05），具有统计学意义。结论人重组干扰素-α-2 b治疗子宫内膜异位症的临床疗效显著，与常规使用戈舍瑞林治疗作用类似，药物不良反应表现在使用早期较多，但持续时间短，停药后皆能自行消失，安全性较高。